1.Evaluation of an alternative dosing regimen with tadalafil, three times per week, for men with erectile dysfunction: SURE study in Italy.
Vincenzo MIRONE ; Ciro IMBIMBO ; Andrea ROSSI ; Riccardo SICUTERI ; Domenico VALLE ; Nicola LONGO ; Ferdinando FUSCO ; null
Asian Journal of Andrology 2007;9(3):395-402
AIMTo examine the preference for two dosing regimens of 20 mg of tadalafil, on demand or three times per week, in men affected with erectile dysfunction (ED) in Italy.
METHODSScheduled Use versus on demand Regimen Evaluation (SURE) is a multicenter, crossover and open-label study, involving 94 urology centers in Italy. Patients aged 18 years or older affected with ED for at least 3 months were enrolled and randomized to 20 mg of tadalafil treatment on demand or three times per week for 5-6 weeks. After a 1-week washout, patients were crossed over to the alternate regimen for 5-6 weeks. A treatment preference question was used to determine the preferred treatment regimen. International Index of Erectile Function (IIEF) and Sexual Encounter Profile (SEP) questionnaire were used as efficacy measures.
RESULTSA total of 1 058 men (mean age 54.8 years), were randomized to treatment. Overall, 59.1% of patients preferred the on-demand regimen and 41.9% preferred the three times per week dosing. Both regimens were efficacious and well tolerated. Although a statistically higher improvement of the IIEF erectile function (IIEF-EF) domain score and the SEP questionnaire was reported for the three times per week compared to the on-demand treatment regimen, this difference was numerically minimal and lacking in clinical significance.
CONCLUSIONTadalafil is effective and well tolerated whether used on demand or three times per week. Patients should be given the option to choose the best treatment regimen according to personal needs and preferences.
Carbolines ; administration & dosage ; therapeutic use ; Cross-Over Studies ; Drug Administration Schedule ; Erectile Dysfunction ; drug therapy ; Humans ; Italy ; Male ; Middle Aged ; Phosphodiesterase Inhibitors ; administration & dosage ; therapeutic use ; Tadalafil ; Treatment Outcome
2.ToleRability of BevacizUmab in elderly Ovarian cancer patients (TURBO study): a case-control study of a real-life experience
Giulia AMADIO ; Claudia MARCHETTI ; Emanuele Rocco VILLANI ; Domenico FUSCO ; Francesca STOLLAGLI ; Carolina BOTTONI ; Mariagrazia DISTEFANO ; Giuseppe COLLOCA ; Giovanni SCAMBIA ; Anna FAGOTTI
Journal of Gynecologic Oncology 2020;31(1):6-
1.1 g/dL, estimated glomerular filtration rate (eGFR) ≤60 mL/min, ≥3 comorbidities were independently associated with a higher severe toxicity.CONCLUSIONS: Elderly patients with EOC can safely be treated with bevacizumab; factors other than age, as higher creatinine serum levels, eGFR and number of comorbidities should be considered to better estimate bevacizumab-related toxicity risk.]]>
Aged
;
Bevacizumab
;
Case-Control Studies
;
Comorbidity
;
Creatinine
;
Diagnosis
;
Drug Therapy
;
Female
;
Glomerular Filtration Rate
;
Humans
;
Logistic Models
;
Ovarian Neoplasms
3.ToleRability of BevacizUmab in elderly Ovarian cancer patients (TURBO study): a case-control study of a real-life experience
Giulia AMADIO ; Claudia MARCHETTI ; Emanuele Rocco VILLANI ; Domenico FUSCO ; Francesca STOLLAGLI ; Carolina BOTTONI ; Mariagrazia DISTEFANO ; Giuseppe COLLOCA ; Giovanni SCAMBIA ; Anna FAGOTTI
Journal of Gynecologic Oncology 2020;31(1):e6-
Objective:
Bevacizumab maintenance following platinum-based chemotherapy is an effective treatment for epithelial ovarian cancer (EOC), both in primary and recurrent disease. Our aim was to identify criteria to select elderly patients who can safely benefit from bevacizumab addition.
Methods:
This is a case-control study on patients with primary or recurrent EOC who received platinum-based chemotherapy plus bevacizumab, between January 2015 and December 2016. Patient characteristics, treatment details and adverse events were reviewed and analyzed in 2 settings: younger (<65 years, group 1) and elderly (≥65 years, group 2). A binary logistic model was applied to correlate clinical variables and severe (grade ≥3) toxicity risk.
Results:
Overall, 283 patients with EOC were included, with 72 (25.4%) older patients compared with 211 (74.6%) younger women. Bevacizumab had been administered to 234 patients (82.7%) as first-line treatment and in 49 (17.3%) with recurrent disease. At diagnosis, elderly patients presented with at least one comorbidity and were taking at least 1 medication in 84.7% and 80.6% of the cases respectively, compared with correspondingly 47.4% and 37.4% in group 1 (p<0.001). Nonetheless, the occurrence of serious (grade ≥3) adverse events did not increase among the older group. Creatinine serum levels >1.1 g/dL, estimated glomerular filtration rate (eGFR) ≤60 mL/min, ≥3 comorbidities were independently associated with a higher severe toxicity.
Conclusions
Elderly patients with EOC can safely be treated with bevacizumab; factors other than age, as higher creatinine serum levels, eGFR and number of comorbidities should be considered to better estimate bevacizumab-related toxicity risk.